Next Article in Journal
Predictors of Positive Radial Margin Status in a Population-Based Cohort of Patients with Rectal Cancer
Previous Article in Journal
Dose-Intensive Chemotherapy with Growth Factor or Autologous Bone Marrow or Stem-Cell Transplant Support in First-Line Treatment of Advanced or Metastatic Adult Soft Tissue Sarcoma: A Clinical Practice Guideline
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 15
Issue 2
10.3747/co.v15i2.224
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

An Approach to the Management of Chronic Myeloid Leukemia in British Columbia

by
D. L. Forrest
1,*,
X. Jiang
2,
C. J. Eaves
2 and
C. L. Smith
1
1
Leukemia/BMT Program of BC, Division of Hematology, General Hospital, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
2
Terry Fox Laboratory, British Columbia Cancer Agency, and Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2008, 15(2), 90-97; https://doi.org/10.3747/co.v15i2.224
Submission received: 3 January 2008 / Revised: 4 February 2008 / Accepted: 8 March 2008 / Published: 1 April 2008

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder whose therapy has changed dramatically since the late 1990s. With the introduction of the tyrosine kinase inhibitor (TKI) imatinib mesylate, the treatment outcomes for patients with CML have improved markedly, and hematopoietic stem-cell transplantation is no longer routinely offered as first-line therapy for most patients in chronic phase. However, resistance to TKI therapy is increasingly being recognized, and alternative therapy is needed for this group of patients. In addition, the development of models predicting response to TKI therapy is desired, so that appropriate treatment strategies can be used for individual patients. The present report serves to outline the approach to the treatment of CML in British Columbia and to highlight areas of ongoing research.
Keywords: chronic myeloid leukemia; treatment guidelines chronic myeloid leukemia; treatment guidelines

Share and Cite

MDPI and ACS Style

Forrest, D.L.; Jiang, X.; Eaves, C.J.; Smith, C.L. An Approach to the Management of Chronic Myeloid Leukemia in British Columbia. Curr. Oncol. 2008, 15, 90-97. https://doi.org/10.3747/co.v15i2.224

AMA Style

Forrest DL, Jiang X, Eaves CJ, Smith CL. An Approach to the Management of Chronic Myeloid Leukemia in British Columbia. Current Oncology. 2008; 15(2):90-97. https://doi.org/10.3747/co.v15i2.224

Chicago/Turabian Style

Forrest, D. L., X. Jiang, C. J. Eaves, and C. L. Smith. 2008. "An Approach to the Management of Chronic Myeloid Leukemia in British Columbia" Current Oncology 15, no. 2: 90-97. https://doi.org/10.3747/co.v15i2.224

APA Style

Forrest, D. L., Jiang, X., Eaves, C. J., & Smith, C. L. (2008). An Approach to the Management of Chronic Myeloid Leukemia in British Columbia. Current Oncology, 15(2), 90-97. https://doi.org/10.3747/co.v15i2.224

Article Metrics

Back to TopTop